An open-label, multi-center long-term safety roll-over study in patients with tuberous sclerosis complex (TSC) and refractory seizures who are judged by the Investigator to benefit from continued t...

Abstract

EudraCT Number: 2016-002977-37
Sponsor Protocol Number: CRAD001M2X02B
Sponsor Name: Novartis Pharma AG
Start Date: 2017-08-25
Medical condition: Refractory seizures associated with tuberous sclerosis complex
Disease:
Version: 20.0
SOC Term: 10010331 - Congenital, familial and genetic disorders
Classification Code: 10045138
Term: Tuberous sclerosis
Level: PT

Population Age: Children, Adolescents, Under 18, Adults
Gender: Male, Female
Trial Protocol: GB (GB - no longer in EU/EEA), HU (Ongoing), ES (Completed), BE (Completed), FR (Completed), PL (Ongoing), IT (Ongoing)